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Abstract
Background: Active fibroblasts, the predominant and the most active cells of breast cancer stroma, are responsible
for tumor growth and spread. However, the molecular mediators and pathways responsible for stromal fibroblast
activation, and their paracrine pro-carcinogenic effects are still not well defined. The CHEK2 tumor suppressor gene
codes for a protein kinase, which plays important roles in the cellular response to various genotoxic stresses.
Methods: Immunoblotting, quantitative RT-PCR and Immunofluorescence were used to assess the expression of
CHEK2 in different primary breast fibroblasts and in tissues. The effect of CHEK2 on the expression and secretion of
SDF-1 and IL-6 was evaluated by immunoblotting and ELISA. The WST-1 colorimetric assay was used to assess cell
proliferation, while the BD BioCoat Matrigel invasion chambers were utilized to determine the effects of CHEK2 on
the migratory and the invasiveness capacities of breast stromal fibroblasts as well as breast cancer cells.
Results: We have shown that CHEK2 is down-regulated in most cancer-associated fibroblasts (CAFs) as compared to
their corresponding tumor counterpart fibroblasts (TCFs) at both the mRNA and protein levels. Interestingly, CHEK2
down-regulation using specific siRNA increased the expression/secretion of both cancer-promoting cytokines SDF-1
and IL-6, and transdifferentiated stromal fibroblasts to myofibroblasts. These cells were able to enhance the proliferation
of non-cancerous epithelial cells, and also boosted the migration/invasion abilities of breast cancer cells in a paracrine
manner. The later effect was SDF-1/IL-6-dependent. Importantly, ectopic expression of CHEK2 in active CAFs converted
these cells to a normal state, with lower migration/invasion capacities and reduced paracrine pro-carcinogenic effects.
Conclusion: These results indicate that CHEK2 possesses non-cell-autonomous tumor suppressor functions, and present
the Chk2 protein as an important mediator in the functional interplay between breast carcinomas and their stromal
fibroblasts.
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Background
Breast tumors, like other types of solid tumors, are com-
posed of cancer cells as well as various types of stromal
cells that constitute the tumor microenvironment [1]. Fi-
broblasts are the most abundant and active stromal cells,
which exhort cancer cells all over the various carcinogenic
steps. Cancer-associated fibroblasts (CAFs)-related pro-
carcinogenic effects are mediated through paracrine factors,
which are under the control of several tumor suppressor
genes such as p16 and p53 [2–4]. In addition to their cell-
autonomous tumor suppressor function, these proteins
possess also non-cell-autonomous tumor suppressive ef-
fects that they manifest from stromal fibroblasts [2].
CHEK2 is another tumor suppressor gene, which is
implicated in the pathogenesis of various types of sporadic
tumors and is a low penetrance-predisposing gene to sar-
coma, brain tumors and familial breast cancer [5]. The
two most studied breast cancer predisposing variants of
the CHEK2 gene are the 100delC deletion in the kinase
domain in exon 10, and the 470 T > C (I157T) missense
mutation in the fork-head-associated (FHA) domain in
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exon 3. These 2 mutations are associated with approxi-
mately 2- fold increased risk of breast cancer [5–7]. A
novel recurrent CHEK2 Y390C mutation has been re-
cently identified in high-risk Chinese breast cancer pa-
tients. This mutation impairs CHEK2 activity and is
associated with increased breast cancer risk [8].
CHEK2 is a multiorgan cancer susceptibility gene that
encodes a multifunctional serine/threonine protein kinase.
CHEK2 enables the link between ATM/ATR kinases and
downstream checkpoint effectors such as p53 during DNA-
damage response [9]. When activated Chk2 phosphorylates
various proteins involved in cell cycle regulation, DNA re-
pair, p53 signaling and apoptosis [9]. Furthermore,
CHEK2 plays also a major role in the senescence-associated
secretory phenotype (SASP). Indeed, the expression of sev-
eral SASP-related cytokines, particularly the inflammatory
cytokines IL-6 and IL-8, is under the control of a pathway
involving CHEK2 [10]. Therefore, in addition to its capital
role in maintaining genomic integrity and preventing fix-
ation of potentially carcinogenic mutations, CHEK2 is also
involved in regulating cellular communication with its
microenvironment. Like senescent cells, cancer-associated
fibroblasts have also a secretary phenotype responsible for
their procarcinogenic effects [11, 12]. Therefore, we sought
to investigate the potential role of CHEK2 in the secretory
phenotype of breast stromal fibroblasts and their activation.
We have shown that CHEK2 inhibits the procarcino-
genic effects of breast stromal fibroblasts and has a non-
cell-autonomous tumor suppressive function through
repressing the expression/secretion of SDF-1 and IL-6.
Methods
Cells, cell culture and chemicals
Breast fibroblast cells were obtained, characterized and
cultured as previously described [13]. Breast tissues were
obtained from patients who underwent surgery at the King
Faisal Specialist Hospital and Research Center. Signed
informed consent was obtained from all the patients
under the Research Ethical Committee Project number
RAC#2031091. While CAFs derived from tumors, TCFs
were developed from histologically normal tissues located
at least 2 cm away from tumors (invasive ductal carcin-
omas). Processing of breast cancer tissues was performed
after routine examination by certified anatomical patholo-
gist using hematoxilin and eosin (HE)-stained sections.
NBF-1 cells were developed from healthy age-matched fe-
male who performed breast reduction surgery. In the
present experiments CAFs and their corresponding TCFs
were always cultured simultaneously, in the same condi-
tions and at similar passages (4–8). MDA-MB-231and
MCF-10A cell lines were obtained from ATCC and were
authenticated before purchase by their standard short tan-
dem repeat DNA typing methodology, and were routinely
tested for the presence of the relevant markers, and were
cultured following the instructions of the company. All
supplements were obtained from Sigma (Saint Louis, MO,
USA) except for antibiotics and antimycotics solutions,
which were obtained from Gibco (Grand Island, NY, USA).
Cells were maintained at 37 °C in humidified incubator
with 5 % CO2.
Anti-SDF-1 (MAB310) and IgG (6-101-C-ABS) from
R&D systems; anti-IL-6 (17901) from Sigma, USA. Block-
ing antibodies were used at 2.5 μg/mL.
RNA purification and quantitative RT-PCR
Total RNA was purified using the TRI reagent (Sigma)
and single stranded complementary DNA (cDNA) was ob-
tained from reverse transcription of 1 μg of RNA using
RT-PCR kit (BD Biosciences) and following the manufac-
turer protocol. cDNA was then amplified with 1U Taq
polymerase, dNTPs (50 mM), and primers (25 pmol each).
For real time RT-PCR Syber green and platinum Taq poly-
merase (Invitrogen) were used and the amplifications were
performed utilizing the Bio-Rad iQ5 multicolor Real time
PCR detection system. All reactions were performed in
triplicates and the data were analyzed using the 2(−Delta











Cells were seeded into 96-well plates at 0.5-1.104/well
and incubated overnight. The medium was replaced with
SFCM and incubated for different time intervals (0, 24
and 48 h). Cell proliferation was measured by the tetra-
zolium salt WST-1 colorimetric assay, as recommended
by the manufacturer (Roche Diagnostics GmbH, Mann-
heim, Germany). The WST-1 reagent was added to each
well, and the plates were then incubated for 4 h at 37 °C.
The amount of formazan was quantified using ELISA
reader at 450 nm of absorbance.
Cellular lysate preparation and immunoblotting
This has been performed as previously described [16]. Anti-
bodies directed against alpha smooth muscle actin (α-
SMA), Stromal-derived factor-1 (SDF-1), Twist-1, Vimentin
(RV202), interleukin-6 (IL-6) and N-cadherin were pur-
chased from Abcam (Cambridge, MA); E-cadherin (24E10),
EpCam (UV1D9), Chk2 (2662) from Cell Signaling (Dan-
vers, MA); p53 (DO-1) and Glyceraldehydes-3-phosphate
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dehydrogenase (GAPDH, FL-335) was purchased from
Santa Cruz (Santa Cruz, CA).
ELISA assays
Supernatants from 24 h fibroblast cell cultures were har-
vested, and ELISA was performed according to the man-
ufacturer’s instructions (R&D Systems). The OD was
used at 450-nm on a standard ELISA plate-reader. These
experiments were performed in triplicates and repeated
at least twice.
Chemotaxis and invasion assay
The 24-well BD BioCoat Matrigel Invasion Chambers were
used as per the manufacturer guideline (BD Bioscience).
2–4 × 105 cells were added to the upper wells separated by
an 8 μm pore size PET membrane with a thin layer of
matrigel basement membrane matrix (for invasion) or
without (for migration). The membranes were stained with
Diff Quick stain (Fisher Scientific) after removing the non-
migrated cells from the top of the membrane with Q-tips.
After air-drying, the membranes were cut and mounted on
slides with oil, and cells that had migrated to the underside
of the filter were counted using light microscope (Zeiss Axio
Observer) in five randomly selected fields (magnification;
40x). Each assay was performed in triplicate.
siRNA transfection
CHEK2-siRNA (SIH600921A) was obtained from SABios-
ciences, and the transfection was performed using lipofec-
tamin (Invitrogen) as recommended by the manufacturer.
Viral infection
Lentivirus based vectors bearing CHEK2-ORF and the
control (Origene, RC212127L1) were used to prepare len-
tiviral supernatant from 293FT cells. Lentiviral superna-
tants were collected 48 h post-transfection, filtered and
used for infection. 24 h later, media were replaced with
complete medium and cells were grown for 3 days.
Conditioned media
Cells were cultured in serum-free medium for 24 h, and
then medium was collected and centrifuged. The result-
ing supernatants were used either immediately or were
frozen at −80 °C until needed.
Quantification of protein expression level
Protein signal intensity of each band was determined
using ImageQuant TL Software (GE Healthcare). Next,
dividing the obtained value of each band by the values of
the corresponding internal control allowed a correction
of the loading differences.
Statistical analysis
Statistical analysis was performed by student’s t-test (two
tailed and unpaired) and p-values < 0.05 were considered
as statistically significant.
Results
CHEK2 is down-regulated in cancer-associated fibroblasts
We started the present study by assessing the level of
the Chk2 protein in CAFs and their corresponding TCFs
(tumor counterpart fibroblasts) isolated from the same
patients. To this end, we prepared whole cell lysates
from 12 CAF/TCF pairs, and then we performed im-
munoblotting analysis using specific Chk2 antibody and
GAPDH was used as internal control. Figure 1a shows
that while Chk2 was undetectable in both CAF-180 and
TCF-180 cells, the level of the protein was reduced in all
the other CAFs as compared to their corresponding TCF
cells. The level of Chk2 was also very low in TCF-87 and
TCF-148 (Fig. 1a). Next, we assessed the expression of
the CHEK2 mRNA level in CAFs and their counterpart
TCFs. Total RNA from the same 12 CAF/TCF pairs was
purified and the CHEK2 mRNA was amplified by quan-
titative RT-PCR (qRT-PCR) using specific primers, and
GAPDH was used as internal control. Figure 1b shows
that the CHEK2 mRNA level was lower in 11 out of 12
CAFs (92 %) as compared to their corresponding TCF
cells. On the other hand, CHEK2 mRNA level was simi-
lar in TCF-900 and CAF-900 cells (Fig. 1b). Therefore,
Fig. 1a and b shows that, in general, there is correlation be-
tween the mRNA and protein expression levels among the
CAF/TCF pairs. For 3 pairs TCF/CAF-118, TCF/CAF-180
and TCF/CAF-900 there was no correlation between the
mRNA and protein levels of CHEK2. This shows that
CHEK2 is down-regulated in most CAFs as compared to
their corresponding TCFs at both the mRNA and protein
levels.
CHEK2 induces p53 but represses the expression of
α-SMA, SDF-1 and IL-6 in breast stromal fibroblasts
After showing the reduced level of CHEK2 in CAFs as
compared to their respective TCFs from the same pa-
tients, we sought to investigate the potential effect of
CHEK2 specific down-regulation on the activation of
these cells. To this end, we knocked-down CHEK2 in
TCF-169 cells and the obtained results were compared
with those of the corresponding CAF-169 cells. Figure 2a
shows efficient down-regulation (6 fold) of Chk2 in TCF-
169 by CHEK2-siRNA as compared to the corresponding
control. This mirrors the expression of Chk2 in TCF-169
and their corresponding CAF-169 cells (Fig. 2a). Interest-
ingly, while the 3 markers α-SMA, IL-6 and SDF-1 were
undetectable in TCF-169 and control-siRNA cells, they
were strongly up-regulated upon CHEK2 down-regulation,
Al-Rakan et al. BMC Cancer  (2016) 16:575 Page 3 of 10
reaching levels similar to those observed in CAF-169
(Fig. 2a). On the other hand, CHEK2 knock-down down-
regulated p53 (6 fold) as compared to control cells, reach-
ing a level similar to that observed in CAF-169 cells
(Fig. 2a). Next, we assessed the effect of CHEK2 down-
regulation on the expression of SDF-1 and IL-6 at the
mRNA levels using qRT-PCR. Figure 2b shows 2 fold in-
crease in the level of SDF-1 and 3 fold up-regulation of IL-
6 in TCF-169-CHEK2-siRNA cells as compared to controls.
This parallels the levels of SDF-1 and IL-6 in TCF-169 and
their corresponding CAF-169 cells (Fig. 2b). This suggests
that CHEK2 represses the expression of these genes in
breast stromal fibroblasts, indicating that CHEK2 down-
regulation may represent an important step towards the ac-
tivation of these cells.
CHEK2 represses the secretion of SDF-1 and IL-6 from
breast stromal fibroblasts
To further show the effect of CHEK2 down-regulation
on the expression of important secreted cytokines, we
assessed the effect of CHEK2 Knock-down on the secre-
tion of SDF-1 and IL-6. To this end, serum-free condi-
tioned media (SFCM) was collected from TCF-169-
CHEK2-siRNA and their corresponding control cells,
and then the secreted levels of SDF-1 and IL-6 was
assessed by ELISA. Figure 2c shows that the down-
regulation of CHEK2 increased the secretion of SDF-1
and IL-6 by 3.3 and 2 fold, respectively. This mirrors the
secreted levels of SDF-1 and IL-6 in TCF-169 and their
corresponding CAF-169 cells (Fig. 2c).
CHEK2 represses the migration/invasion abilities of breast
stromal fibroblasts
Next, we examined the effect of CHEK2 down-regulation
on the migratory and invasiveness abilities of stromal fibro-
blasts. To this end, TCF-169-CHEK2-siRNA cells as well as
their respective controls were seeded with SFM in the
upper inserts of BD bio-coat™ chambers (BD biosciences)
(without matrigel, for migration) or coated with matrigel
layer (for invasion), while complete media was added as a
chemo-attractant to the lower wells of the chambers. Cells
were then incubated overnight to allow migration and in-
vasion. Figure 3a shows that TCF-169-CHEK2-siRNA cells
were 2- and 3- fold more motile and invasive than their
controls, respectively. Similar results were obtained when
CHEK2 was knocked-down using the same siRNA in the
normal breast stromal fibroblasts NBF-1 (Fig. 3b). These
results mirror the migration/invasion abilities of TCF-169
and their corresponding CAF-169 (Fig. 3c). This indicates
that CHEK2 represses the migration/invasion abilities of
breast stromal fibroblasts.
Fig. 1 CHEK2 expression is down-regulated in cancer-associated fibroblasts. a Whole cell lysates were prepared from the indicated cells and 50 μg of
proteins were used for immunoblotting analysis using antibodies against the indicated proteins. b Total RNA was extracted from the indicated cells
and the amount of the CHEK2 mRNA was assessed by qRT-PCR. Error bars represent means ± S.D
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CHEK2 down-regulation in breast stromal fibroblasts
enhances the proliferation of epithelial cells in a
paracrine manner
To confirm the active status of CHEK2-defective fibroblasts,
we tested the paracrine procarcinogenic effects of these fi-
broblasts. To this end, we first examined the effect of
CHEK2 down-regulation in stromal fibroblasts on the prolif-
eration of epithelial cells utilizing indirect co-culturing.
Therefore, SFCM was collected from TCF-169-CHEK2-
siRNA cells and the corresponding control cells, and were
used for culturing the non-cancerous MCF-10A and the
cancer MDA-MB-231 epithelial cells seeded in 96 well
plates. Cell proliferation was assessed using the WST-1 re-
agent. Figure 4 shows that after 24 h and 48 h of incuba-
tion, SFCM from TCF-169-CHEK2-siRNA enhanced cell
proliferation as compared to SFCM from control cells, in
both cell lines. This indicates that CHEK2 down-
regulation in breast stromal fibroblasts enhances their
ability in increasing the proliferation of breast epithelial
cells via paracrine signaling.
CHEK2 down-regulation in breast stromal fibroblasts
promotes the migration/invasion abilities of breast cancer
cells in an SDF-1/IL-6-dependent manner
We have next studied the effect of CHEK2 down-regulation
in stromal fibroblasts on the migration and invasion abil-
ities of breast cancer MDA-MB-231 cells. Therefore, these
cells were seeded in the upper inserts of the migration and
invasion chambers in the presence of SFCM from TCF-
169-CHEK2-siRNA and control cells, while the lower in-
serts of the chambers contained SFM. Cells were incubated
overnight to allow migration and invasion under the attrac-
tion force of the chemo-attractants that are present in the
SFCM. MDA-MB-231 cells that migrated/invaded were
fixed, stained and counted in 5 random fields. Figure 5a
shows that MDA-MB-231 cells that were exposed to SFCM
from TCF-169-CHEK2-siRNA had higher migration/inva-
sion activities as compared to cells exposed to SFCM from
the corresponding control cells. Indeed, SFCM from
CHEK2-deficient cells enhanced the migration and invasion
abilities of MDA-MB-231 cells 2- and 7- fold as compared
Fig. 2 CHEK2 represses the expression/secretion of SDF-1 and IL-6. a Whole cell lysates were prepared from the indicated cells and were used for
immunoblotting analysis. The numbers below the bands indicate the corresponding expression levels after loading correction against GAPDH.
b Total RNA was extracted from the indicated cells and used to assess the mRNA levels of SDF-1 and IL-1 using qRT-PCR and specific primers.
c Conditioned media from the indicated cells were collected after 24 h and the levels of the indicated proteins were determined by ELISA, and
were presented in the respective histograms. Error bars represent means ± S.D, *, p value < 0.0001
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to control cells, respectively (Fig. 5a). These results provide
evidence that CHEK2 down-regulation in breast stromal fi-
broblasts increases the paracrine pro-migration and -inva-
sion of cancer cells, which further confirms the active
status of CHEK2-deficient breast stromal fibroblasts.
Next, we sought to investigate the possible role of SDF-1
and IL-6 in the paracrine effects of CHEK2-deficient cells.
To this end, both cytokines were inhibited either separately
or simultaneously using specific neutralizing antibodies in
the SFCM from TCF-169-CHEK2-siRNA. Anti-IgG was
also used as negative control. MDA-MB-231 cells were in-
cubated with these media, and then the migration/invasion
abilities of these cells were studied as described above.
Figure 5b shows that the inhibition of SDF-1 reduced by 2
Fig. 4 CHEK2 deficient fibroblasts enhance the proliferation of epithelial cells in a paracrine manner. SFCM were collected from TCF-169-CHEK2-siRNA
cells and their controls, and then were added to MCF10A (a) or MDA-MB-231 (b) cells that were seeded on 96-well plates. The proliferation was
measured at the indicated times using the WTS-1 assay. Error bars represent ± SD, p value < 0.0001
Fig. 3 CHEK2 represses the migration/invasion abilities of breast stromal fibroblasts. TCF-169-CHEK2-siRNA cells and their controls (a), NBF-1-CHEK2-siRNA
cells and their controls (b) as well as CAF-169 and TCF-169 cells (c) were seeded with SFM in the inserts of BD bio-coat™ chambers (BD biosciences)
(without matrigel, for migration) or coated with matrigel layer (for invasion), while complete media was added as a chemo-attractant to the lower wells
of the chambers. After 24 h of incubation, cells were stained with Diff-Quick stain then counted. Upper panels: images of the invaded and migrated
cells. Histograms: Average numbers of invaded and migrated cells. Error bars represent means ± S.D, *, p value < 0.0001
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fold the migration potential of breast cancer cells as com-
pared to cells exposed to anti-IgG. Interestingly, the inhib-
ition of IL-6 was more potent, reducing the migration to a
level similar to that obtained by the double inhibition (7
fold lower as compared to the control). In addition, the in-
hibition of SDF-1, IL-6 or both in SFCM collected from
TCF-169-CHEK2-siRNA reduced the invasion potential of
breast cancer cells 2.5, 5 and 6 fold, respectively (Fig. 5b).
This shows that the paracrine IL-6 effect on the migration/
invasion of breast cancer cells is stronger than that of SDF-
1, and that the pro-migratory/-invasiveness effects of
CHEK2-deficient stromal fibroblasts is mediated through
increase in the secretion of SDF-1 and IL-6, which are in
normal situations repressed by CHEK2.
CHEK2 down-regulation in breast stromal fibroblasts
enhances the epithelial-to-mesenchymal transition of
breast cancer cells in a paracrine manner
To further study the effect of CHEK2 down-regulation on
breast cancer cells, we investigated the paracrine effect of
CHEK2 deficient fibroblasts on the mesenchymal and epi-
thelial markers of MDA-MB-231 cells. These cells were
treated with SFM conditioned with TCF-169-CHEK2-
siRNA or TCF-169-control-siRNA for 24 h. Subsequently,
protein extracts were prepared and used for immunoblot-
ting analysis using specific antibodies for EMT markers.
Figure 5c shows that the levels of the epithelial
markers E-cadherin and Epcam were reduced 2.3 and
12 fold in MDA-MB-231 cells treated with SFCM
Fig. 5 CHEK2-deficient fibroblast secretions stimulate invasion/migration in an SDF1- and IL-6-dependent manner and enhance mesenchymal features in
breast cancer cells. a SFCM were collected after 24 h of incubation from TCF-169-CHEK2-siRNA and their control cells, and were added to MDA-MB-231 cells
(105) that were seeded onto the upper compartment of the plates and incubated for 24 h. The numbers of invaded and migrated cells were presented in
histograms. Error bars represent means ± S.D. *: p value <0.001, as compared to the control lane 1. b MDA-MB-231 cells were treated as indicated, and then
the migration and invasion abilities were assessed as described in A. c MDA-MB-231 cells were treated with SFCM from the indicated cells for 24 h, and
then cell lysates were prepared and used for immunoblotting analysis using the indicated antibodies
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from TCF-169-CHEK2-siRNA as compared to SFCM
from control cells. On the other hand, the levels of
the mesenchymal markers N-cadherin, Twist1 and
vimentin were 2.3, 12 and 3 fold higher in breast can-
cer cells treated with SFCM from TCF-169-CHEK2-
siRNA as compared to SFCM from control cells
(Fig. 5c). This indicates that SFCM from CHEK2-defi-
cient fibroblast cells can enhance the EMT process in
breast cancer cells.
Ectopic expression of CHEK2 suppresses the procarcinogenic
features of cancer-associated fibroblasts
In an effort to further confirm the role of CHEK2 in sup-
pressing the procarcinogenic features of breast stromal fi-
broblasts, we next investigated the effects of CHEK2
ectopic expression in CAF-169 cells, wherein CHEK2 level
was shown to be very low (Fig. 1a). Therefore, CAF-169
cells were transfected with a lenti-virus-based plasmid
bearing CHEK2-ORF (CAF-169-CHEK2-ORF), and an
empty vector was used as control. Whole cell lysates
were prepared and used for immunoblotting analysis.
Figure 6a shows that the Chk2 level was 2.3 fold
higher in CAF-169-CHEK2-ORF cells as compared to
the controls. Interestingly, ectopic expression of the
CHEK2 gene in CAF-169 cells strongly reduced the
level of both SDF-1 and IL-6 (Fig. 6a). These levels
mirror the SDF-1 and IL-6 levels observed in TCF-
169 cells (Fig. 2b). This finding further supports the
role of CHEK2 in suppressing the expression of SDF-
1 and IL-6. Next, we studied the migratory and the
invasiveness abilities of CAF-169-CHEK2-ORF cells,
using BD chambers. While complete medium was
added as a chemo-attractant to the lower wells of the
chambers, cells were added to the upper wells in the
presence of SFM. Figure 6b shows that ectopic ex-
pression of CHEK2 reduced the motility (40 %) and
the invasiveness (34 %) of active CAF-169 cells as
compared to control cells. This confirms that CHEK2
represses the migration/invasion abilities in breast
stromal fibroblasts.
To further show the role of CHEK2 in suppressing the
procarcinogenic effects of CAFs, we investigated the para-
crine effect of CHEK2 expression on the migration/inva-
sion capacities of MDA-MB-231. Cells were seeded in the
inserts of BD chambers, and SFM conditioned with CAF-
169-CHEK2-ORF cells (SFCM-CHEK2-ORF) as well as
control cells (SFCM-control) were placed in the lower
wells of the chambers. Cells were incubated overnight to
allow migration and invasion. Figure 6c shows that SFCM-
CHEK2-ORF reduced the motility (3 fold) and the inva-
siveness (2.5 fold) of breast cancer MDA-MB-231 cells as
compared to SFCM-control. This further confirms that
CHEK2 represses the paracrine pro-migration/invasion ef-
fects of breast stromal fibroblasts. Together, these re-
sults indicate that ectopic expression of the CHEK2
gene in the active CAF-169 fibroblasts transforms these
cells to a normal state.
Fig. 6 CHEK2 upregulation represses breast stromal fibroblasts and their paracrine procarcinogenic effects. CAF-169 cells transfected with CHEK2-ORF
(CAF-169-CHEK2-ORF) or control plasmid (CAF-169-control). a Whole cell lysates were prepared from the indicated cells and were used for
immunoblotting analysis. The numbers below the bands indicate the corresponding expression levels after loading correction against
GAPDH. b Assessment of the migration/invasion abilities of CAF-169 cells expressing either CHEK2 ORF or control plasmid as described in Fig. 3. c SFCM
were collected after 24 h of incubation from CAF-169-CHEK2-ORF cells (SFCM-CHEK2-ORF) and control cells (SFCM-control), and then were added to
MDA-MB-231 cells. The migration and invasion abilities were assessed as described in Fig. 5a. Error bars represent means ± S.D. *: p value <0.001
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Discussion
Myofibroblasts actively contribute to the growth, expan-
sion and dissemination of neoplastic epithelial cells. How-
ever, the genes and pathways controlling myofibroblast-
related tumor-promoting effects are not fully delineated.
Several lines of evidence indicate the implication of tumor
suppressor genes in controlling the procarcinogenic effects
of stromal fibroblasts in a paracrine manner [2, 3]. In the
present study we have shown that the tumor suppressor
Chk2 protein plays an important role in controlling mam-
mary stromal fibroblast autocrine and paracrine signaling.
Indeed, CHEK2 is down-regulated in CAFs as compared to
their corresponding TCFs, isolated from the same patients.
In addition, we have seen inter-individual variation in the
CHEK2 expression among TCF cells. This could be due to
different tumor features such as the stage or the grade.
Similar differences were previously observed for p16 [3].
The CHEK2 decrease suggests a role of cancer cells in sup-
pressing CHEK2 expression in fibroblast cells present in
their vicinity, either directly or indirectly. In fact, several
lines of evidence indicate that neoplastic cells have the
ability to affect their microenvironment and modulate gene
expression through secreted factors [17, 18]. This in
principle leads to the activation of stromal cells, which in
turn fuel the carcinogenic process and promote tumor
growth and spread through functional cross-talk with
tumor cells. To study the role of CHEK2 down-regulation
in these processes, we specifically down-regulated this gene
in breast stromal fibroblasts using specific siRNA, and we
studied the consequent autocrine and paracrine effects. We
have shown that CHEK2 down-regulation activates
breast stromal fibroblasts and enhances their paracrine
procarcinogenic effects. Indeed, CHEK2-defective cells ex-
hibited higher migratory and invasive capacities, expressed
lower levels of p53 and higher levels of the myofibroblast
markers α-SMA and SDF-1, and enhanced the migration/
invasion abilities of breast cancer cells and their mesen-
chymal features in a paracrine manner. Indeed, CHEK2
down-regulation in fibroblasts paracrinaly induced the
three major mesenchymal markers N-cadherin, Twist-1
and vimentin, and decreased two major epithelial markers
E-cadherin and Epcam in breast cancer cells. This indi-
cates that CHEK2-defective breast stromal fibroblasts en-
hance the pro-metastatic EMT process in epithelial cells
in a paracrine manner. On the other hand, ectopic expres-
sion of CHEK2 repressed the migratory/invasiveness abil-
ities of active breast stromal fibroblasts as well as their
paracrine effects on breast cancer cells. This confirmed
the suppressive role of CHEK2 in the procarcinogenic ef-
fects of breast stromal fibroblasts.
The present data showed also that in addition to its
autonomous tumor suppressor function, CHEK2 has also
a non-cell-autonomous tumor suppressor activity. This
paracrine effect is mediated through controlling the
expression/secretion of the pro-carcinogenic cytokines
SDF-1 and IL-6, may be through p53 down-regulation.
Indeed, p53 represses the expression of both SDF-1 and
IL-6 [19, 20], which are important promoters of tumor
growth and progression [11, 12]. Furthermore, specific
inhibition of secreted SDF-1 or IL-6 suppressed the pro-
migratory/invasiveness effects of CHEK2-deficient stro-
mal fibroblasts. Interestingly, the double blockage had
an inhibitory effect similar to that obtained by the inhib-
ition of IL-6 alone, which was stronger than SDF-1 in-
hibition (Fig. 5). This indicates that the effects of IL-6
and SDF-1 inhibition were synergistic despite the fact
that the 2 molecules act through different receptors and
pathways, however, a potential functional interaction be-
tween the activated pathways is possible.
In addition to Chk2, other important tumor suppressor
proteins such as p16, p21, p53, PTEN and CAV-1 are also
implicated in repressing the procarcinogenic effects of
breast stromal fibroblasts both in vitro and in vivo [2, 3,
19, 21–24]. This clearly shows that these tumor suppres-
sor proteins represses breast carcinogenesis in both epi-
thelial as well as stromal cells.
Conclusions
The present findings have shown that in addition to its
well-known cell-autonomous tumor suppressor func-
tion within incipient pro-carcinogenic epithelial cells,
stromal fibroblast CHEH2, like other tumor suppressor
genes, exerts also non-cell-autonomous effects in breast
tumorigenesis. Therefore, stromal fibroblast CHEK2might
constitute a valid therapeutic target to stop tumor pro-
gression and/or recurrence.
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